SUSQUEHANNA INTERNATIONAL GROUP, LLP - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 123 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 1.40 and the average weighting 0.1%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$1,190,000
-39.7%
350,000
-33.4%
0.00%
Q2 2018$1,975,000
-6.5%
525,199
+1.7%
0.00%
Q1 2018$2,113,000
-41.2%
516,600
-33.1%
0.00%
-100.0%
Q4 2017$3,593,000
-27.8%
772,685
+10.2%
0.00%
-50.0%
Q3 2017$4,979,000
-29.8%
701,206
-28.6%
0.00%
-50.0%
Q2 2017$7,097,000
+0.2%
981,608
-14.6%
0.00%0.0%
Q1 2017$7,080,000
+26.9%
1,149,275
+20.7%
0.00%
+100.0%
Q4 2016$5,578,000
+15.0%
951,956
+4.2%
0.00%0.0%
Q3 2016$4,850,000
-9.2%
913,222
+13.2%
0.00%
-33.3%
Q2 2016$5,341,000
+12.6%
806,867
-20.5%
0.00%0.0%
Q1 2016$4,742,000
-1.6%
1,015,352
+6.4%
0.00%0.0%
Q4 2015$4,820,000
+54.7%
954,393
+7.9%
0.00%
+200.0%
Q3 2015$3,115,000
-71.5%
884,882
-19.2%
0.00%
-75.0%
Q2 2015$10,931,000
-9.8%
1,095,252
+15.1%
0.00%
-20.0%
Q1 2015$12,118,000
-21.6%
951,870
-12.8%
0.01%
-28.6%
Q4 2014$15,451,000
-39.3%
1,091,948
-41.0%
0.01%
-30.0%
Q3 2014$25,446,000
+15.9%
1,850,631
+29.7%
0.01%0.0%
Q2 2014$21,951,000
+2.0%
1,427,288
+13.0%
0.01%0.0%
Q1 2014$21,531,000
-18.3%
1,263,510
-37.9%
0.01%
-9.1%
Q4 2013$26,362,000
+38.1%
2,035,680
+7.7%
0.01%0.0%
Q3 2013$19,084,000
+118.3%
1,889,487
+61.4%
0.01%
+120.0%
Q2 2013$8,742,0001,170,4100.01%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q4 2016
NameSharesValueWeighting ↓
VHCP Management, LLC 700,273$10,770,0005.76%
HARVEY CAPITAL MANAGEMENT INC 932,400$14,340,0005.13%
Camber Capital Management LP 3,000,000$46,140,0003.02%
Baupost Group 10,539,986$162,105,0002.64%
SECTORAL ASSET MANAGEMENT INC 3,741,656$57,547,0002.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,884,409$59,742,0002.40%
Knoll Capital Management, LLC 200,000$3,076,0001.37%
DAFNA Capital Management LLC 92,400$1,421,0001.35%
NORTHPOINTE CAPITAL LLC 892,011$13,719,0001.32%
Rhenman & Partners Asset Management AB 240,000$3,691,0001.10%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders